SCHEMBL2767699

SCHEMBL2767699

CCCCCCCCCC(=O)N1CCN(c2cc(F)c(OC)cc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.60
LMNA P02545 4/20 0.60
ALDH1A1 P00352 2/20 0.60
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
HIF1A Q16665 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 1/20 0.47
FFAR4 Q5NUL3 1/20 0.47
GPR174 Q9BXC1 1/20 0.47
GNAI3 P08754 1/20 0.45
GNAI1 P63096 1/20 0.45
TP53 P04637 1/20 0.44
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768597 0.84 LMNA (0.64) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL28523079 0.80 HTR1A (0.67) LMNAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL28907245 0.80 HTR1A (0.67) LMNAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2767625 0.80 KMT2A (0.65) ALDH1A1MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL22892309 0.79 MAPT (0.57) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL3463893 0.77 MAPT (0.47) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL28527312 0.74 HTR1A (0.60) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL28519578 0.74 HTR1A (0.60) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL22892230 0.73 MEN1 (0.56) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL28528626 0.73 CNR1 (0.61) MAPTLMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA MAPT 4852/4885LMNA 3963/4885ALDH1A1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.